Treprostinil Palmitil Inhalation Powder + Placebo

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pulmonary Hypertension

Conditions

Pulmonary Hypertension, Interstitial Lung Disease

Trial Timeline

Jan 7, 2026 → Dec 30, 2028

NCT ID

NCT07179380

About Treprostinil Palmitil Inhalation Powder + Placebo

Treprostinil Palmitil Inhalation Powder + Placebo is a phase 3 stage product being developed by Insmed for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07179380. Target conditions include Pulmonary Hypertension, Interstitial Lung Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07481981	Phase 3	Recruiting	Apr 17, 2026	Jan 28, 2029	Pulmonary Arterial Hypertension
NCT07234032	Phase 3	Recruiting	Apr 1, 2026	Jan 22, 2031	Pulmonary Hypertension
NCT07179380	Phase 3	Recruiting	Jan 7, 2026	Dec 30, 2028	Pulmonary Hypertension
NCT05649722	Phase 2/3	Active	May 11, 2023	Mar 14, 2026	Pulmonary Hypertension
NCT06091579	Phase 1	Completed	Sep 17, 2020	Jan 12, 2021	Healthy Volunteers

Competing Products

20 competing products in Pulmonary Hypertension

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
macitentan 10 mg	BML, Inc.	Phase 3	76
tadalafil + tadalafil	Eli Lilly	Phase 3	77
CS1 Administration	Cereno Scientific	Phase 2	47
CS1	Cereno Scientific	Pre-clinical	18
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	52
DS-1040b + Placebo + Enoxaparin	Daiichi Sankyo	Phase 1/2	41
DS-9231 + Placebo	Daiichi Sankyo	Phase 2	52
Regadenoson	Astellas Pharma	Pre-clinical	23
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	52
Monteplase	Eisai	Approved	85
lysozyme 90 mg + Placebo	Eisai	Approved	85
Prednisolone + Voriconazole	Cipla	Phase 2/3	65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)	Eli Lilly	Phase 2	52
tadalafil and ambrisentan upfront combination therapy	Eli Lilly	Approved	85

Other Products from Insmed

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3

Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3

ALIS + Azithromycin + Ethambutol + ELCPhase 3

LAI 590 mg + Multi-drug regimenPhase 3

Liposomal amikacin for inhalationPhase 3